DGAP-Adhoc: Eckert & Ziegler: Record Income and Sales in 2015. Strong Rise in Net Liquidity. Hasselmann joins BEBIG Management Board.

Eckert & Ziegler Strahlen- und Medizintechnik AG  / Key word(s): Dividend

21.03.2016 19:31

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Berlin, March 21, 2016 - Eckert & Ziegler AG, a specialist for
isotope-based applications in medicine, science and industry, finished
fiscal year 2015 with new records in terms of income and sales. As the
Supervisory Board stated at its balance sheet meeting on Monday, net profit
for the year was EUR 10.7 million, or EUR 2.03 per share - the best result
since the company's founding. Sales exceeded EUR 140 million. Net
liquidity, the amount by which cash and cash equivalents exceeded
liabilities, grew as of December 31, 2015 by EUR 12.8 million to EUR 15.9
million, reaching the highest value since 2012.

At the Annual General Meeting on June 8, 2016, the Executive Board and the
Supervisory Board will propose a dividend of EUR 0.60 per share entitled to
a dividend (prior year: EUR 0.60).


---------------------------------------------------------------------------

Information and Explanation of the Issuer to this News:

In terms of content, the annual financial statements were influenced by a
series of one-off effects. Extraordinary income from the sale of an
investment was offset by losses in the Radiation Therapy segment and an
increase in risk provisioning. With regard to sales and income, the Group
also benefited from the lower external value of the euro. The detailed
figures will be published on March 23, 2016.

As part of the reorganization of the Radiation Therapy segment, plans are
in place to transfer Dr. Edgar Löffler's position as Executive Director on
the Board of Directors of Eckert & Ziegler BEBIG s.a. to Dr. Harald
Hasselmann at mid-year. Dr. Löffler will remain a member of the Executive
Board of Eckert & Ziegler AG, where he will continue to be responsible for
the Radiation Therapy segment.

For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de

21.03.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Eckert & Ziegler Strahlen- und Medizintechnik AG
              Robert-Rössle-Str.10
              13125 Berlin
              Germany
Phone:        49 30 941084-138
Fax:          49 30 941084-112
E-mail:       karolin.riehle@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700
WKN:          565970
Listed:       Regulated Market in Frankfurt (Prime Standard), Stuttgart;
              Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg,
              Munich
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------